샘플 요청 목록

 카트 문의
시장보고서
상품코드
1772265

트렘피아(Tremfya) 시장 : 규모, 점유율, 동향 분석, 용도별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

Tremfya Market Size, Share & Trends Analysis Report By Application (Plaque Psoriasis, Psoriatic Arthritis (PsA)), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

트렘피아 시장 요약

트렘피아 세계 시장 규모는 2024년에 36억 7,000만 달러로 평가되었고, 2033년에는 72억 9,000만 달러에 이를 것으로 예측되며, 2025년부터 2033년까지의 CAGR은 7.60%를 나타낼 전망입니다. 만성 판상 건선과 건선성 관절염의 유병률 증가는 선진 생물학적 제형에 대한 수요를 증가시키고 있습니다.

이러한 자가면역 질환은 전 세계적으로 계속 증가하고 있으며, 그 결과 효과적이고 장기적인 치료 옵션에 대한 요구가 증가하고 있습니다. 인터루킨-23(IL-23)을 표적으로 하는 단일클론항체인 트렘피아는 중등도에서 중증의 경우에 강한 효능과 지속적인 결과를 가져옵니다. 그것의 일관된 임상 성적과 좋은 안전 프로파일은 피부과 의사와 류마티스 전문의 사이에서 받아 들여지고 있습니다.

얀센 파머슈티칼스의 강력한 시장 전략과 경쟁 포지셔닝은 트렘피아의 상업적 성공을 뒷받침하고 있습니다. 이 약물은 TNF 억제제 및 IL-17 억제제를 포함한 여러 기존 생물학적 제제와 비교하여 우수한 효능 데이터로 차별화되었습니다. 대면 연구에 따르면 트렘피아의 신속한 피부 클리어런스와 지속적인 효능을 달성하는 능력을 보여 주며, 치료 상황에서 전략적 이점을 제공합니다. 예를 들어, 2024년 10월, 존슨 엔드 존슨의 SPECTREM 실험은 트렘피아가 두피, 얼굴, 손, 발, 생식기 등의 건선 곤란 부위를 효과적으로 클리어했으며, 클리어율은 최대 80%인 것으로 나타났습니다. 대부분의 환자는 48주까지 피부를 맑게 유지하거나 거의 투명한 피부를 유지했습니다. 이 치료는 또한 가려움증과 통증과 같은 증상을 완화하고 환자의 삶의 질을 크게 향상시켰습니다.

현재 진행중인 임상연구와 라이프사이클 매니지먼트의 대처가 트렘피아 시장의 향후 성장을 지지하고 있습니다. 정밀의료와 바이오마커 주도형 치료에 대한 관심 증가는 맞춤형 치료 요법에서 IL-23 억제제의 관련성을 높이고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 트렘피아 시장의 변수, 동향, 범위

  • 시장 계통 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 비즈니스 환경 분석
    • 업계 분석 - Porter's Five Forces 분석
    • PESTLE 분석
    • 파이프라인 분석
    • 특허 만료 분석
    • 가격 분석

제4장 트렘피아 시장 : 용도의 비즈니스 분석

  • 용도 시장 점유율, 2024년 및 2033년
  • 용도 부문 대시보드
  • 시장 규모, 예측, 동향 분석(용도별, 2021-2033년)
  • 심상성 건선
  • 건선성 관절염(PsA)
  • 기타

제5장 트렘피아 시장 : 유통 채널의 비즈니스 분석

  • 유통 채널 시장 점유율, 2024년 및 2033년
  • 유통 채널 부문 대시보드
  • 시장 규모, 예측, 동향 분석(유통 채널별, 2021-2033년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제6장 트렘피아 시장 : 지역의 추정 및 예측 분석

  • 지역별 시장 점유율 분석, 2024년 및 2033년
  • 지역 시장 대시보드
  • 시장 규모와 예측 동향 분석, 2021-2033년:
  • 북미
    • 국가별, 2021년-2033년
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제7장 경쟁 구도

  • 참가자 개요
  • 기업의 시장 포지셔닝 분석
  • 기업 분류
  • 전략 매핑
  • 기업 프로파일/상장 기업
    • Johnson &Johnson Services, Inc.
SHW 25.07.23

Tremfya Market Summary

The global tremfya market size was estimated at USD 3.67 billion in 2024 and is projected to reach USD 7.29 billion by 2033, growing at a CAGR of 7.60% from 2025 to 2033. The increasing prevalence of chronic plaque psoriasis and psoriatic arthritis drives greater demand for advanced biologic therapies.

These autoimmune conditions continue to rise globally, resulting in a growing need for effective and long-term treatment options. Tremfya, a monoclonal antibody that targets interleukin-23 (IL-23), has delivered strong efficacy and durable outcomes in moderate-to-severe cases. Its consistent clinical performance and favorable safety profile have strengthened its acceptance among dermatologists and rheumatologists.

Janssen Pharmaceuticals ' strong marketing strategies and competitive positioning drive Tremfya's commercial success. The drug has differentiated itself through superior efficacy data compared to some existing biologics, including TNF and IL-17 inhibitors. Head-to-head studies have shown Tremfya's ability to achieve rapid skin clearance and sustained response, giving it a strategic advantage in the treatment landscape. For instance, In October 2024, Johnson & Johnson's SPECTREM study showed Tremfya effectively cleared difficult psoriasis areas like the scalp, face, hands, feet, and genitals, with clearance rates up to 80%. Most patients maintained clear or almost clear skin through week 48. The treatment also significantly improved patients' quality of life by reducing symptoms like itch and pain.

Ongoing clinical research and lifecycle management initiatives support the Tremfya market's future growth. New clinical trials are exploring expanded applications, such as hidradenitis suppurativa and Crohn's disease, which could significantly widen its therapeutic scope. The drug's manufacturer also invests in real-world evidence studies to validate its effectiveness in diverse populations. The growing interest in precision medicine and biomarker-driven therapies is increasing the relevance of IL-23 inhibitors in personalized treatment regimens. Partnerships with specialty pharmacies and streamlined distribution networks enhance availability in high-demand markets. The company's continued focus on physician education and patient support programs reinforces brand loyalty.

Global Tremfya Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Tremfya market report based on application, distribution channel and region:

  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Plaque Psoriasis
  • Psoriatic Arthritis (PsA)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Tremfya Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Tremfya Market: Application Business Analysis

  • 4.1. Application Market Share, 2024 & 2033
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 4.4. Plaque Psoriasis
    • 4.4.1. Plaque Psoriasis Market, 2021 - 2033 (USD Million)
  • 4.5. Psoriatic Arthritis (PsA)
    • 4.5.1. Psoriatic Arthritis (PsA) Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Tremfya Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 6. Tremfya Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Tremfya Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Tremfya Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Johnson & Johnson Services, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Application Benchmarking
      • 7.5.1.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제